We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim
News

Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim

Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim
News

Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Axxam Announces Two Discovery Collaboration Agreements with Boehringer Ingelheim"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Axxam announced that the discovery research and services company has entered into two drug research collaboration agreements with Boehringer Ingelheim.

The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening and lead optimization through the joint efforts of Axxam and Boehringer Ingelheim researchers.

The second agreement covers the transfer of protein material and a corresponding specific functional assay for high-throughput screening to Boehringer Ingelheim.

“Axxam is proud to partner with Boehringer Ingelheim to advance their drug discovery program,” said Dr. Stefan Lohmer, Chairman and Chief Executive Officer at Axxam.

“These two agreements recognize our reputation as a quality provider of key components of early-stage drug discovery – gene expression and functional assay development for high-throughput screening.”

Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.

Further financial details of the agreements are not disclosed.

Advertisement